secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022122
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q3 net loss $6.3M; Veris relaunches implant monitor; Lucid gets Medicare support
--------------------------------------------------------------------------------

- GAAP net loss $6.3M ($0.29 diluted EPS); non-GAAP adj loss $0.4M ($0.02) for Q3 2025.
- Lucid Diagnostics: $1.2M EsoGuard revenue, 2,841 tests processed; CAC unanimously supported Medicare coverage.
- Veris Health launched commercial phase of OSU partnership, relaunched implantable monitor for planned 2026 FDA submission.
- PAVmed signed LOI with Duke University to license endoscopic esophageal imaging technology via new subsidiary.
- PAVmed cash $3.1M (Sep 30) vs $1.2M (Dec 31, 2024); Lucid netted ~$27M from public offering.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/0001493152-25-022122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315225022122/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer